New FDA Groups For Rare, Neglected Diseases Could Speed Path To Market
This article was originally published in The Gray Sheet
Executive Summary
Two new FDA review groups to recommend solutions for the prevention, diagnosis and treatment of rare diseases and neglected diseases of the developing world would help get treatments to market faster, patient advocates and lawmakers say